Monitoring of Systemic Light-Chain Amyloidosis patients using Mass Spectrometry (M-inSight) in serum
During ASH 2023 and in collaboration with the CHU of Limoges, Sebia presented the possibility to monitor disease burden of AL amyloidosis patient from AMYDARA clinical trial as well as patients in the clinic. The poster shows that MRD monitoring on blood is feasible, using an ultra-sensitive MS technique, avoiding invasive bone-marrow aspirate. M-inSight can track low level AL disease.